Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Developments in glucocorticoid therapy.

Johannes W J Bijlsma1, Kenneth G Saag, Frank Buttgereit

  • 1Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Box 85500, 3508 GA Utrecht, The Netherlands. j.w.j.bijlsma@azu.nl

Rheumatic Diseases Clinics of North America
|January 11, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low-dose and very low-dose glucocorticoids: which low is low risk? - Authors' reply.

The Lancet. Rheumatology·2026
Same author

Teclistamab for treatment-refractory autoimmune diseases: a multicentre case series.

Annals of the rheumatic diseases·2026
Same author

Secukinumab for Giant Cell Arteritis.

NEJM evidence·2026
Same author

Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica.

The New England journal of medicine·2026
Same author

Comment on: Recommendations of the German, Austrian and Swiss rheumatology and other medical societies for the management of polymyalgia rheumatica: reply.

Rheumatology (Oxford, England)·2026
Same author

Changes in bone mineral density and fractures during 2 years of low-dose glucocorticoid treatment for rheumatoid arthritis: a systematic literature review and individual participant data meta-analysis.

RMD open·2026

Low-dose glucocorticoids show disease-modifying potential for rheumatoid arthritis. New GC compounds and better toxicity management may improve the risk-benefit ratio of this therapy.

Area of Science:

  • Rheumatology
  • Pharmacology
  • Immunology

Background:

  • Rheumatoid arthritis (RA) treatment involves balancing efficacy and adverse effects.
  • Low-dose glucocorticoids (GCs) are being re-evaluated for disease-modifying potential in RA.
  • The risk-benefit profile of GC therapy in RA requires ongoing assessment.

Purpose of the Study:

  • To review recent advancements in glucocorticoid (GC) therapy for rheumatoid arthritis.
  • To explore how new GC compounds and improved toxicity management can enhance the risk-benefit ratio.
  • To discuss the evolving role of GCs in modifying RA disease progression.

Main Methods:

  • Literature review of recent evidence on glucocorticoid therapy in rheumatoid arthritis.
  • Analysis of developments in novel glucocorticoid compounds and formulations.

Related Experiment Videos

  • Examination of strategies for improved management of glucocorticoid-induced toxicity.

    • Main Results:

    • Emerging evidence suggests disease-modifying capabilities of low-dose GCs in RA.
    • Development of "designer" GCs with altered bioactivity and formulations offers potential improvements.
    • Enhanced understanding and management strategies for GC toxicity are emerging.

    Conclusions:

    • Advancements in GC compounds and toxicity management may positively impact the risk-benefit ratio of GC therapy in RA.
    • Low-dose GCs represent a promising therapeutic avenue for rheumatoid arthritis.
    • Further research into optimized GC formulations and toxicity mitigation is warranted.